 LONDON, Feb. 21, 2022 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022. 